BioSpace News Archive

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a grant from the Bill & Melinda Gates Foundation of $3.4 million to scale up production batch size to allow for increased capacity of Dynavax’s CpG 1018 advanced adjuvant to support the global COVID-19 response. These efforts will support capacity of up to 750 million adjuvant d

Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve outcomes, announces it has entered into an agreement with a healthcare group

InMode Ltd. (Nasdaq: INMD) (“InMode”), a leading global provider of innovative medical technologies, is pleased to announce a new FDA clearance to market the Morpheus8 Body handpiece and Morpheus8 Platform.

Observational study results demonstrate improved blood pressure and glycemic control for patients suffering from hypertensive blood pressure and diabetes who used the Dario platform [13-August-2020] NEW YORK , Aug. 13, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that an emerging science in

Neptune Wellness Solutions Inc. (“Neptune” or the “Company”) (NASDAQ: NEPT) (TSX: NEPT), a diversified and fully integrated health and wellness company focused on natural, plant-based, sustainable and purpose-driven lifestyle brands, is pleased to announce that its subsidiary, Neptune Health & Wellness Innovation, In

$106,000 Grant Supports Work to Predict Organ Travel Time and Pilot Real-Time Tracking

Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today reported its financial results for the quarter ended June 30, 2020 . Business Highlights for 2020 to date. During the First Half of 2020, the Company achieved the followi

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced it has completed the design process for an advanced handpiece and cartridge for its Rapid Acoustic Pulse (RAP) device

--Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 for Patients with Advanced Solid Tumors Harboring a KRAS G12C Mutation--

Despite progress in massively parallel sequencing there remains a gap in our ability to characterize mRNA splicing in cancer due to read-length limitations of short-read sequencing and accuracy limitations of long-read sequencing.